ELAN:NYE-Elanco Animal Health (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 12.67

Change

+0.11 (+0.88)%

Market Cap

USD 6.18B

Volume

2.90M

Analyst Target

USD 26.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.09 (+0.05%)

USD 85.62B
RDY Dr. Reddy’s Laboratories Ltd..

-59.38 (-80.25%)

USD 63.63B
TAK Takeda Pharmaceutical Co Ltd A..

+0.17 (+1.21%)

USD 44.45B
HLN Haleon plc

+0.01 (+0.10%)

USD 43.99B
CTLT Catalent Inc

-0.21 (-0.36%)

USD 10.78B
BHC Bausch Health Companies Inc

+0.43 (+4.64%)

USD 3.56B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.16 (-1.90%)

USD 2.55B
CPHI China Pharma Holdings Inc

-0.01 (-3.80%)

USD 4.03M
YCBD cbdMD Inc

-0.01 (-2.17%)

USD 2.11M
PRGO Perrigo Company PLC

-0.06 (-0.24%)

N/A

ETFs Containing ELAN

PETZ:LSE 11.16 % 0.00 %

N/A

N/A
KATZ:XETRA 9.20 % 0.00 %

N/A

N/A
PETZ:SW 9.20 % 0.00 %

N/A

N/A
XGLF:F db x-trackers MSCI GCC Se.. 5.83 % 0.00 %

-0.09 (0%)

USD 0.02B
WTD7:F WisdomTree Issuer ICAV - .. 1.49 % 0.00 %

-0.07 (0%)

USD 0.06B
WTES:F WisdomTree Issuer ICAV - .. 1.49 % 0.00 %

-0.29 (0%)

USD 0.06B
DFE:SW WisdomTree Europe SmallCa.. 1.25 % 0.00 %

N/A

N/A
DFEA:SW WisdomTree Europe SmallCa.. 1.25 % 0.00 %

N/A

N/A
DFE WisdomTree Europe SmallCa.. 0.00 % 0.58 %

+0.49 (+0%)

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.41 (+0%)

N/A
XGLF:LSE db x-trackers MSCI GCC Se.. 0.00 % 0.00 %

+0.03 (+0%)

N/A
WTD7:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

-0.02 (0%)

USD 0.06B
WTES:XETRA WisdomTree Europe SmallCa.. 0.00 % 0.00 %

N/A

USD 0.06B
XGLF:XETRA Xtrackers MSCI GCC Select.. 0.00 % 0.00 %

-0.09 (0%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.97% 27% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.97% 27% F 22% F
Trailing 12 Months  
Capital Gain 18.41% 40% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.41% 40% F 58% F
Trailing 5 Years  
Capital Gain -52.93% 36% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.93% 36% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -3.12% 33% F 20% F
Dividend Return -3.12% 33% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.13% 47% F 22% F
Risk Adjusted Return -7.24% 33% F 18% F
Market Capitalization 6.18B 50% F 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector